Global Neglected Tropical Diseases Diagnostics Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Disease;
Dengue, Chikungunya, Rabies, Leprosy, Buruli Ulcer, Yaws, Lymphatic Filariasis, Taeniasis/Cysticercosis, Foodborne Trematodiases, Echinococcosis, Chagas Disease (American Trypanosomiasis), Dracunculiasis, African Trypanosomiasis, Soil-transmitted Helminth Infections, Onchocerciasis, Schistosomiasis, Scabies and Other Ectoparasites, Snakebite Envenoming and Leishmaniasis.By Diagnostic Method;
Conventional Methods and Molecular/Modern Method.By Service;
Centralized Service and Point-of-care testing (POCT).By End Use;
Clinical Labs, Hospitals/Clinics and Home Healthcare.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).Introduction
Global Neglected Tropical Diseases Diagnostics Market (USD Million), 2021 - 2031
In the year 2024, the Global Neglected Tropical Diseases Diagnostics Market was valued at USD 7,237.58 million. The size of this market is expected to increase to USD 9,653.11 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 4.2%.
The global neglected tropical diseases (NTDs) diagnostics market is a vital component in the fight against a group of diseases that disproportionately affect populations in low-resource settings. NTDs, comprising a diverse range of infectious diseases such as dengue fever, Chagas disease, and schistosomiasis, often thrive in impoverished and neglected communities, leading to significant morbidity and mortality. Diagnosing these diseases accurately and promptly is crucial for effective treatment, disease surveillance, and control efforts, making diagnostics a cornerstone of global health initiatives targeting NTDs.
One of the primary drivers of the global NTDs diagnostics market is the increasing recognition of the burden posed by these diseases on public health and socio-economic development. Governments, international organizations, and philanthropic foundations have intensified efforts to combat NTDs, leading to expanded funding for research, prevention, and control programs. As a result, there is growing demand for innovative and affordable diagnostic tools capable of detecting NTDs in diverse settings, from rural villages to urban slums.
Technological advancements in diagnostics are revolutionizing the landscape of NTD detection and surveillance. Rapid diagnostic tests (RDTs), molecular assays, and point-of-care (POC) devices are increasingly being deployed to improve the accuracy, speed, and accessibility of NTD diagnosis. These innovations enable healthcare providers to diagnose NTDs in resource-limited settings with limited laboratory infrastructure, facilitating early detection, treatment initiation, and disease monitoring.
Despite significant progress, the global NTDs diagnostics market faces several challenges, including limited access to healthcare services, particularly in remote and underserved areas. Affordability, regulatory hurdles, and quality control issues pose barriers to the widespread adoption of NTD diagnostic tools. However, amidst these challenges lie opportunities for market players to collaborate with governments, non-profit organizations, and public health agencies to develop and deploy innovative diagnostic solutions tailored to the needs of affected communities, ultimately contributing to the control and elimination of NTDs on a global scale.
Global Neglected Tropical Diseases Diagnostics Market Recent Developments
-
In October 2023 , The World Health Organization (WHO) introduced a pilot scheme for an Expert Review Panel for Diagnostic Products (ERPD) for neglected tropical diseases (NTDs). This initiative aimed to improve quality assurance and accessibility of NTD diagnostic tools for healthcare providers.
-
In january 2024, The African region accelerated the global roadmap for neglected tropical diseases (NTDs), with ten countries eliminating at least one NTD since 2021. Togo eliminated four, Egypt eradicated lymphatic filariasis, and Morocco ceased trachoma as a public health problem.
Segment Analysis
The global neglected tropical diseases (NTDs) diagnostics market is experiencing significant growth due to the increasing prevalence of various diseases such as dengue, chikungunya, rabies, leprosy, and others. These diseases disproportionately affect populations in low- and middle-income countries, where access to healthcare and diagnostic services may be limited. The rising burden of NTDs has prompted government initiatives and funding programs aimed at disease control and prevention, driving the demand for diagnostic tools and technologies to aid in early detection and management.
Within the NTDs landscape, diagnostics play a crucial role in disease surveillance, differential diagnosis, and treatment monitoring. Conventional diagnostic methods, such as microscopy, serology, and culture-based techniques, have traditionally been used for NTD diagnosis. However, the advent of molecular and modern diagnostic methods, including PCR, nucleic acid amplification tests (NAATs), and rapid antigen tests, has revolutionized NTD diagnostics by offering improved sensitivity, specificity, and turnaround times. These advancements have enabled more accurate and timely detection of NTDs, facilitating prompt initiation of treatment and disease control efforts.
The end-use of NTD diagnostics encompasses various settings, including clinical labs, hospitals/clinics, and home healthcare settings. Clinical labs and hospitals/clinics serve as primary points of care for NTD diagnosis, offering centralized diagnostic services and expertise. However, with the increasing emphasis on decentralized healthcare delivery and community-based interventions, there is a growing demand for point-of-care testing (POCT) solutions that enable rapid and onsite diagnosis of NTDs. POCT devices provide convenience, accessibility, and timely results, particularly in resource-limited settings where access to centralized healthcare facilities may be challenging.
Geographically, the NTD diagnostics market spans across regions such as North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. While NTDs predominantly affect populations in tropical and subtropical regions, they also pose a growing threat in non-endemic areas due to factors such as globalization, travel, and climate change. As a result, there is a need for comprehensive NTD control and surveillance strategies across all regions, driving the demand for diagnostics solutions tailored to local epidemiological contexts and healthcare infrastructures. The global NTD diagnostics market is expected to witness continued growth and innovation, fueled by ongoing research, technological advancements, and collaborative efforts aimed at combating these debilitating diseases.
Global Neglected Tropical Diseases Diagnostics Segment Analysis
In this report, the Global Neglected Tropical Diseases Diagnostics Market has been segmented by Disease, Diagnostic Method, Service, End Use and Geography.
Global Neglected Tropical Diseases Diagnostics Market, Segmentation by Disease
The Global Neglected Tropical Diseases Diagnostics Market has been segmented by Disease into Dengue, Chikungunya, Rabies, Leprosy, Buruli Ulcer, Yaws, Lymphatic Filariasis, Taeniasis/Cysticercosis, Foodborne Trematodiases, Echinococcosis, Chagas Disease (American Trypanosomiasis), Dracunculiasis, African Trypanosomiasis, Soil-transmitted Helminth Infections, Onchocerciasis, Schistosomiasis, Scabies and Other Ectoparasites, Snakebite Envenoming and Leishmaniasis.
Neglected tropical diseases (NTDs) encompass a group of debilitating and often life-threatening infections that primarily affect populations living in poverty-stricken regions with limited access to healthcare. Dengue, Chikungunya, and Zika virus infections, transmitted by Aedes mosquitoes, are significant contributors to the global burden of NTDs. These vector-borne diseases cause fever, joint pain, and rash, and can lead to severe complications such as hemorrhagic fever and neurological disorders. Rapid and accurate diagnostics are essential for timely detection and management of these viral infections, particularly in endemic areas where outbreaks are common.
Rabies, transmitted through the bite of infected animals, remains a deadly zoonotic disease that affects millions of people worldwide, primarily in Asia and Africa. Leprosy, caused by Mycobacterium leprae, leads to skin lesions, nerve damage, and deformities if left untreated. Despite significant progress in disease control, leprosy diagnosis remains challenging, particularly in regions with limited healthcare infrastructure. Buruli ulcer, Yaws, and lymphatic filariasis are neglected bacterial and parasitic infections that cause disfiguring skin lesions, debilitating joint deformities, and lymphedema, respectively. Accurate diagnostic tools are crucial for early detection and treatment to prevent long-term disability and transmission in affected communities.
Taeniasis/Cysticercosis, foodborne trematodiases, echinococcosis, and Chagas disease are neglected parasitic infections with significant public health implications. Taeniasis/Cysticercosis, caused by Taenia solium tapeworms, can lead to cysticercosis, a potentially fatal condition affecting the brain and other organs. Foodborne trematodiases, transmitted through the consumption of contaminated raw or undercooked seafood, affect millions of people in endemic regions, causing liver and intestinal damage. Echinococcosis, caused by Echinococcus tapeworms, results in cyst formation in vital organs, posing diagnostic challenges and treatment complexities. Chagas disease, caused by Trypanosoma cruzi parasites, is a leading cause of heart disease and death in Latin America, underscoring the importance of accurate diagnostics for disease surveillance and control.
Dracunculiasis, African trypanosomiasis, soil-transmitted helminth infections, onchocerciasis, schistosomiasis, scabies, other ectoparasites, snakebite envenoming, and leishmaniasis represent additional NTDs with diverse clinical manifestations and transmission routes. These diseases disproportionately affect marginalized populations in resource-limited settings, where access to diagnostics and treatment is often inadequate. The development and deployment of innovative, affordable, and accessible diagnostic tools are essential for effectively combating NTDs, reducing disease burden, and achieving global health equity. Collaborative efforts among governments, public health agencies, non-profit organizations, and the private sector are critical for advancing NTD diagnostics and improving health outcomes for vulnerable populations worldwide.
Global Neglected Tropical Diseases Diagnostics Market, Segmentation by Diagnostic Method
The Global Neglected Tropical Diseases Diagnostics Market has been segmented by Diagnostic Method into Conventional Methods and Molecular/Modern Method.
Conventional methods have long been utilized for the diagnosis of neglected tropical diseases (NTDs), offering simplicity and affordability, particularly in resource-limited settings. These methods often involve the use of microscopy, serological tests, and antigen detection assays to identify NTD pathogens or their associated antibodies in patient samples. While conventional diagnostic methods are cost-effective and widely available, they may lack sensitivity and specificity, leading to potential false-positive or false-negative results. The reliance on skilled laboratory personnel and infrastructure can pose challenges in remote or underserved regions, limiting the reach and effectiveness of NTD control programs.
In contrast, molecular and modern diagnostic methods have revolutionized NTD diagnostics by offering enhanced sensitivity, specificity, and speed of detection. Techniques such as polymerase chain reaction (PCR), nucleic acid amplification tests (NAATs), and next-generation sequencing (NGS) allow for the direct detection of NTD pathogens' genetic material in patient samples, enabling early and accurate diagnosis. Modern molecular methods offer multiplexing capabilities, allowing simultaneous detection of multiple pathogens in a single test, which is particularly advantageous for diseases with overlapping symptomatology or co-infections. The adoption of molecular methods may be hindered by their higher cost, complexity, and infrastructure requirements, limiting their accessibility in low-resource settings.
The advent of point-of-care (POC) molecular diagnostics has addressed some of the challenges associated with traditional laboratory-based molecular methods, offering rapid, decentralized testing capabilities in near-patient settings. POC molecular diagnostic platforms, such as loop-mediated isothermal amplification (LAMP) and cartridge-based systems, provide rapid results within minutes to hours, enabling timely diagnosis and treatment initiation in remote or underserved areas. POC molecular tests often require minimal sample preparation and technical expertise, making them suitable for use by non-specialized healthcare workers in community-based settings. As such, POC molecular diagnostics hold great promise for enhancing NTD control efforts, particularly in regions with limited laboratory infrastructure and skilled personnel.
Despite the advancements in molecular and modern diagnostic methods, conventional techniques continue to play a crucial role in NTD diagnostics, especially in resource-constrained settings where cost, simplicity, and accessibility are paramount. Efforts to improve the affordability, scalability, and integration of molecular diagnostics into existing NTD control programs are underway, aiming to expand access to accurate and timely diagnosis for all individuals affected by NTDs. Ultimately, a combination of conventional and molecular diagnostic methods, tailored to the specific needs and resources of each setting, is essential for achieving effective NTD control and elimination on a global scale.
Global Neglected Tropical Diseases Diagnostics Market, Segmentation by Service
The Global Neglected Tropical Diseases Diagnostics Market has been segmented by Service into Centralized Service and Point-of-care testing (POCT).
In the global neglected tropical diseases (NTDs) diagnostics market, centralized service and point-of-care testing (POCT) play crucial roles in disease detection and management. Centralized services involve diagnostic testing conducted in specialized laboratories equipped with advanced equipment and skilled personnel. These centralized facilities offer comprehensive testing capabilities, allowing for the accurate diagnosis of a wide range of NTDs. Centralized testing is particularly beneficial for complex diagnostic procedures requiring sophisticated equipment and expertise, ensuring reliable results and facilitating disease surveillance and control efforts on a larger scale.
On the other hand, point-of-care testing (POCT) brings diagnostic capabilities directly to the patient's bedside or within the community setting. POCT devices are portable, user-friendly, and designed to deliver rapid results, enabling timely diagnosis and treatment initiation. POCT is especially valuable in resource-limited settings where access to centralized laboratories may be limited or where immediate diagnosis is essential for patient management. By providing real-time diagnostic information, POCT enhances healthcare delivery, facilitates targeted interventions, and improves patient outcomes, particularly in remote or underserved areas where NTDs are prevalent.
Centralized services and POCT complement each other in the NTDs diagnostics landscape, addressing different needs and contexts within healthcare systems. While centralized services offer comprehensive testing capabilities and quality assurance measures, POCT fills the gap by providing rapid, on-the-spot diagnostic results where access to centralized laboratories is limited. By leveraging both approaches, healthcare providers can enhance the efficiency and effectiveness of NTDs diagnostic strategies, enabling timely detection, treatment, and surveillance of these neglected diseases.
Advancements in technology are driving innovation in both centralized services and POCT for NTDs diagnostics. Centralized laboratories are adopting automated platforms, molecular techniques, and high-throughput screening methods to improve diagnostic accuracy, efficiency, and throughput. Meanwhile, POCT devices are becoming increasingly sophisticated, with advancements in miniaturization, connectivity, and multiplexing capabilities. These technological innovations are expanding the diagnostic capabilities of both centralized services and POCT, making NTDs diagnostics more accessible, accurate, and efficient, ultimately contributing to improved patient care and disease control efforts.
Global Neglected Tropical Diseases Diagnostics Market, Segmentation by End Use
The Global Neglected Tropical Diseases Diagnostics Market has been segmented by End Use into Clinical Labs, Hospitals/Clinics and Home Healthcare.
In clinical labs, the global neglected tropical diseases (NTDs) diagnostics market witnesses a concerted effort to enhance diagnostic accuracy and efficiency. These labs serve as pivotal hubs for disease detection, employing advanced diagnostic technologies and methodologies to identify NTDs promptly and accurately. With a focus on precision and reliability, clinical labs play a vital role in supporting healthcare providers and public health agencies in their efforts to combat NTDs by providing timely and accurate diagnostic results. Moreover, clinical labs contribute to disease surveillance and epidemiological studies, providing valuable data for monitoring NTD prevalence and distribution patterns, thus guiding targeted intervention strategies.
Hospitals and clinics represent crucial frontline settings for NTD diagnosis and management, catering to a diverse patient population presenting with various symptoms and healthcare needs. In these settings, NTD diagnostics are integrated into comprehensive healthcare services, facilitating prompt diagnosis, treatment initiation, and patient management. Healthcare professionals in hospitals and clinics leverage a range of diagnostic tools and techniques to assess patients suspected of NTDs, including serological tests, molecular assays, and imaging modalities. The multidisciplinary nature of hospital settings enables collaboration between different specialties, fostering a holistic approach to NTD diagnosis and care delivery.
In the realm of home healthcare, the global NTD diagnostics market is witnessing a shift towards decentralized testing and patient-centered care models. Home healthcare settings offer convenience, accessibility, and personalized care to individuals affected by NTDs, allowing for timely diagnosis and management in the comfort of patients' homes. Portable and user-friendly diagnostic devices play a key role in home-based NTD diagnostics, enabling patients to monitor their health status and disease progression with minimal intervention from healthcare professionals. Home healthcare services empower patients to actively participate in their care and treatment decisions, promoting patient empowerment and self-management of NTDs under appropriate guidance and supervision.
Global Neglected Tropical Diseases Diagnostics Market, Segmentation by Geography
In this report, the Global Neglected Tropical Diseases Diagnostics Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Neglected Tropical Diseases Diagnostics Market Share (%), by Geographical Region, 2024
In North America, the neglected tropical diseases (NTDs) diagnostics market is expected to witness steady growth during the forecast period. This growth can be attributed to increasing awareness about NTDs among healthcare professionals and the general population, leading to improved screening and diagnostic efforts. The presence of well-established healthcare infrastructure and diagnostic facilities enables efficient disease detection and management. Government initiatives and funding for NTD control programs contribute to the expansion of diagnostic services, particularly in underserved communities.
In Europe, the NTDs diagnostics market is poised for significant growth owing to rising efforts by governments and healthcare organizations to address NTDs within the region. Increasing research and development activities focused on developing innovative diagnostic technologies and solutions are expected to drive market growth. Collaborations between academic institutions, research organizations, and healthcare providers contribute to advancements in disease detection and management. The implementation of screening programs and initiatives aimed at raising awareness about NTDs further propel market expansion.
The Asia Pacific region presents substantial opportunities for growth in the NTDs diagnostics market due to the high prevalence of NTDs and the large population at risk. Governments and healthcare organizations in countries such as India, China, and Southeast Asian nations are increasingly focusing on NTD control programs, which include strengthening diagnostic capabilities. The growing adoption of point-of-care diagnostic tools and mobile health technologies enhances access to diagnostic services, particularly in remote and rural areas. Collaborations with international organizations and non-profit groups support efforts to combat NTDs effectively.
In the Middle East, Africa, and Latin America regions, the NTDs diagnostics market faces unique challenges but also presents significant growth opportunities. Limited access to healthcare services, particularly in rural and underserved areas, poses challenges for disease diagnosis and management. However, increasing investments in healthcare infrastructure and initiatives aimed at improving access to diagnostic services are expected to drive market growth. Partnerships between governments, international organizations, and non-profit entities play a crucial role in expanding diagnostic capabilities and addressing the burden of NTDs in these regions. The NTDs diagnostics market in these regions is expected to witness steady growth as efforts to combat NTDs intensify and healthcare systems strengthen.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Neglected Tropical Diseases Diagnostics Market. These factors include; Market Drivers, Restraints and Opportunities.
Drivers, Restraints and Opportunity
Drivers:
- Technological Advancements in Diagnostics
- Rising Awareness and Screening Efforts for NTDs
-
Expansion of Healthcare Infrastructure in Developing Regions-The expansion of healthcare infrastructure in developing regions plays a crucial role in shaping the global neglected tropical diseases (NTDs) diagnostics market. As these regions experience rapid population growth and urbanization, governments and international organizations are investing in healthcare infrastructure to improve access to medical services, including diagnostics for NTDs. The establishment of primary healthcare centers, community clinics, and mobile health units enables healthcare providers to reach underserved populations in remote areas where NTDs are prevalent.
The expansion of healthcare infrastructure facilitates the deployment of diagnostic technologies for NTDs in resource-limited settings. With improved access to laboratory facilities, diagnostic equipment, and trained healthcare personnel, healthcare providers can conduct accurate and timely tests for NTDs, leading to earlier detection, treatment, and control of these diseases. This enhanced diagnostic capacity is essential for achieving global health goals and reducing the burden of NTDs in endemic regions.
The integration of NTD diagnostics into existing healthcare infrastructure enables comprehensive disease surveillance and monitoring efforts. By incorporating diagnostic testing for NTDs into routine healthcare services, healthcare providers can identify cases more efficiently, track disease trends, and implement targeted interventions to prevent transmission and outbreaks. This proactive approach to disease control is critical for achieving sustainable improvements in public health outcomes and reducing the socioeconomic impact of NTDs on affected communities.
The expansion of healthcare infrastructure creates opportunities for collaboration between governments, non-profit organizations, and private sector stakeholders to strengthen NTD control programs. By leveraging the resources and expertise of various partners, healthcare systems in developing regions can implement innovative strategies for NTD diagnosis, treatment, and prevention. These collaborative efforts contribute to the overall resilience and sustainability of healthcare infrastructure, ensuring that diagnostic services for NTDs remain accessible and effective in the face of emerging challenges and evolving healthcare needs.
Restraints:
- Affordability and Accessibility of Diagnostics in Low-Income Settings
- Challenges in Differential Diagnosis and Disease Surveillance
-
Regulatory Hurdles and Quality Control Concerns-Regulatory hurdles present significant challenges for the global neglected tropical diseases (NTDs) diagnostics market. Due to the diverse nature of NTDs and the wide range of pathogens they encompass, regulatory agencies often struggle to establish clear and standardized guidelines for diagnostic tests. This lack of uniformity can lead to delays in the approval process for new diagnostic technologies, hindering their availability for use in affected regions. Regulatory requirements vary between countries and regions, further complicating the market landscape and increasing the time and resources required for compliance.
Quality control concerns also pose notable obstacles to the NTDs diagnostics market. Ensuring the accuracy, reliability, and consistency of diagnostic tests is essential for effective disease management and treatment. However, maintaining stringent quality control measures can be challenging, particularly in resource-limited settings where infrastructure and laboratory facilities may be lacking. Inadequate quality control protocols can result in false positives or negatives, leading to misdiagnosis, inappropriate treatment, and potential public health risks such as the spread of drug-resistant strains.
The complexity of NTDs and the wide range of pathogens involved necessitate diagnostic tests with high specificity and sensitivity. Achieving these performance metrics while maintaining cost-effectiveness and ease of use presents a significant challenge for diagnostic manufacturers. Balancing the need for accuracy with affordability and accessibility is crucial for ensuring widespread adoption of NTD diagnostics, particularly in low-resource settings where financial constraints may limit healthcare spending.
Addressing regulatory hurdles and quality control concerns requires collaboration between governments, regulatory agencies, healthcare organizations, and diagnostic manufacturers. Establishing clear regulatory pathways, harmonizing standards across regions, and investing in quality assurance programs are essential steps towards overcoming these challenges. Fostering partnerships and knowledge sharing initiatives can facilitate the development and deployment of innovative diagnostic solutions tailored to the unique needs of NTD-affected populations, ultimately improving disease surveillance, treatment outcomes, and public health interventions.
Opportunities:
- Expansion into Emerging Markets with High NTD Burden
- Integration of Diagnostics with Multidisciplinary NTD Control Programs
-
Investment in Research and Development for Novel Diagnostic Solutions-Investment in research and development (R&D) for novel diagnostic solutions holds immense promise for advancing the diagnosis and management of neglected tropical diseases (NTDs) worldwide. With NTDs affecting millions of people in low-resource settings, there is a pressing need for innovative diagnostic tools that are affordable, accessible, and capable of providing accurate and timely results. R&D efforts in this area aim to address the unique challenges associated with NTD diagnostics, such as the diverse range of pathogens involved, the complexity of disease transmission dynamics, and the limited healthcare infrastructure in affected regions.
These R&D endeavors encompass a wide range of approaches, including the development of point-of-care (POC) diagnostic devices, novel assay platforms, and molecular diagnostic techniques tailored specifically for NTDs. POC diagnostic tools, in particular, hold great promise for overcoming barriers to access and enabling timely diagnosis and treatment initiation in remote and underserved areas where laboratory infrastructure is limited. By investing in the development of user-friendly, low-cost POC devices, researchers and manufacturers aim to democratize access to NTD diagnostics and improve healthcare outcomes for affected populations.
Collaboration between academia, industry, non-profit organizations, and public health agencies is instrumental in driving forward R&D efforts for novel NTD diagnostic solutions. These partnerships leverage diverse expertise, resources, and funding sources to accelerate the development and validation of innovative diagnostic technologies. By pooling together knowledge and resources, stakeholders can overcome common challenges such as regulatory hurdles, quality control standards, and the validation of diagnostic accuracy across different geographic regions and population groups.
Investment in R&D for novel NTD diagnostic solutions not only addresses the immediate needs of affected populations but also contributes to broader efforts in disease surveillance, control, and elimination. By enhancing the sensitivity, specificity, and scalability of diagnostic tools, researchers and innovators are laying the groundwork for more effective NTD control programs, targeted intervention strategies, and evidence-based decision-making in public health. Ultimately, continued investment in R&D for NTD diagnostics holds the potential to transform the landscape of NTD control and elimination, bringing us closer to achieving global health equity and the Sustainable Development Goals.
Competitive Landscape Analysis
Key players in Global Neglected Tropical Diseases Diagnostics Market include:
- F. Hoffmann-La Roche Ltd
- Abbott
- Thermo Fisher Scientific, Inc
- ZeptoMetrix
- InBios International, Inc
- Genome Diagnostics Pvt. Ltd
- Omega Diagnostics Group PLC
- Coris Bioconcept SPRL
- DiaSys Diagnostic Systems GmbH
- Oscar Medicare Pvt Ltd
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Disease
- Market Snapshot, By Diagnostic Method
- Market Snapshot, By Service
- Market Snapshot, By End Use
- Market Snapshot, By Region
- Global Neglected Tropical Diseases Diagnostics Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Technological Advancements in Diagnostics
- Rising Awareness and Screening Efforts for NTDs
- Expansion of Healthcare Infrastructure in Developing Regions
- Restraints
- Affordability and Accessibility of Diagnostics in Low-Income Settings
- Challenges in Differential Diagnosis and Disease Surveillance
- Regulatory Hurdles and Quality Control Concerns
- Opportunities
- Expansion into Emerging Markets with High NTD Burden
- Integration of Diagnostics with Multidisciplinary NTD Control Programs
- Investment in Research and Development for Novel Diagnostic Solutions
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Neglected Tropical Diseases Diagnostics Market, By Disease, 2021 - 2031 (USD Million)
- Dengue
- Chikungunya
- Rabies
- Leprosy
- Buruli Ulcer
- Yaws
- Lymphatic Filariasis
- Taeniasis/Cysticercosis
- Foodborne Trematodiases
- Echinococcosis
- Chagas Disease (American Trypanosomiasis)
- Dracunculiasis
- African Trypanosomiasis
- Soil-transmitted Helminth Infections
- Onchocerciasis
- Schistosomiasis
- Scabies and Other Ectoparasites
- Snakebite Envenoming
- Leishmaniasis
- Global Neglected Tropical Diseases Diagnostics Market, By Diagnostic Method, 2021 - 2031 (USD Million)
- Conventional Methods
- Molecular/Modern Method
- Global Neglected Tropical Diseases Diagnostics Market, By Service, 2021 - 2031 (USD Million)
- Centralized Service
- Point-of-care testing (POCT)
- Global Neglected Tropical Diseases Diagnostics Market, By End Use, 2021 - 2031 (USD Million)
- Clinical Labs
- Hospitals/Clinics
- Home Healthcare
- Global Neglected Tropical Diseases Diagnostics Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia/New Zealand
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Neglected Tropical Diseases Diagnostics Market, By Disease, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- F. Hoffmann-La Roche Ltd
- Abbott
- Thermo Fisher Scientific, Inc
- ZeptoMetrix
- InBios International, Inc
- Genome Diagnostics Pvt. Ltd
- Omega Diagnostics Group PLC
- Coris Bioconcept SPRL
- DiaSys Diagnostic Systems GmbH
- Oscar Medicare Pvt Ltd
- Company Profiles
- Analyst Views
- Future Outlook of the Market